Dr. Ana Martinez is Research Professor at Medicinal Chemistry Institute of Spanish National Council for Research (CSIC), having a background formation on Organic Chemistry. Her interest is focused on neurodegenerative disorders, leading numerous research projects on the medicinal chemistry and rational drug design of new drugs for Alzheimer's and Parkinson's disease, amyotrophic lateral sclerosis, spinal cord trauma and multiple sclerosis. Active areas of research involve GSK-3 inhibitors, BACE inhibitors, PDE 7 inhibitors, neurogenic drugs, CK 1 inhibitors among others. Since February 2002 till January 2008, she joined to NeuroPharma, currently named NOSCIRA, as R&D Director where she has provided strategic, leadership management and guidance in R&D activities, being two of her research compounds, named NP-12 and NP-61, in clinical trials as disease modifying agents for Alzheimer's disease. She is author of more than a hundred and fifty scientific publications, more than twenty active patents in the field and editor of several books.